{"id":"NCT01223703","sponsor":"Universit√† degli Studi di Brescia","briefTitle":"PUFAs and Left Ventricular Function in Heart Failure","officialTitle":"Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2010-10-19","resultsPosted":"2011-07-25","lastUpdate":"2012-01-31"},"enrollment":133,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dilated Cardiomyopathy","Heart Failure"],"interventions":[{"type":"DRUG","name":"n-3 PUFAs","otherNames":["OMACOR, Pronova Biopharma, Lysaker, Norway"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"n-3 PUFAs","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to test the hypothesis that n-3 PUFAs improve left ventricular systolic function in patients with stable chronic HF secondary to nonischemic dilated cardiomyopathy (NICM).","primaryOutcome":{"measure":"Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up","timeFrame":"one year","effectByArm":[{"arm":"n-3 PUFAs","deltaMin":36,"sd":7},{"arm":"Placebo","deltaMin":37,"sd":6}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":1,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}